#VisualAbstract SWOG-1211: Addition of elotuzumab to RVd induction and maintenance (lenalidomide, bortezomib, dexamethasone) did not improve patient outcomes in untreated, high-risk multiple myeloma

byKathleen Lau

January 14, 2021

in StudyGraphics

#VisualAbstract: Durvalumab, trametinib, and dabrafenib triplet therapy may provide robust immunogenicity in patients with BRAF-mutated advanced melanoma

RelatedReports

Endocrinology

Sodium-glucose co-transporter-2 inhibitors may decrease risk of in-stent thrombosis

March 24, 2023

Thrombophilia-associated stillbirth risk appears limited to factor V Leiden

Cardiology

Active surveillance strategies to improve rates of inferior vena cava filter retrieval

March 22, 2023

Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact

Chronic Disease

Nivolumab plus ipilimumab does not improve survival in post-nephrectomy patients with renal cell carcinoma

March 21, 2023

Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs

Chronic Disease

Adenoma detection rate is inversely associated with post-colonoscopy colorectal cancer risk

March 20, 2023

Prescription of antibiotics for acute respiratory infections increasing

Common hospital complications associated with COVID-19 identified in a retrospective cohort study

Novel coronavirus identified from patients with pneumonia in Wuhan, China

O and Rh– blood groups may be associated with decreased risk for SARS-CoV-2 infection

#VisualAbstract AMLSG 09-09: Adding getuzumab ozogamicin (GO) to intensive therapy for Nucleophosmin1 mutated acute myeloid leukemia (NPM1mut AML) leads to better NPM1mut transcript clearance and a lower replase rate

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

#VisualAbstract SWOG-1211: Addition of elotuzumab to RVd induction and maintenance (lenalidomide, bortezomib, dexamethasone) did not improve patient outcomes in untreated, high-risk multiple myeloma

Sodium-glucose co-transporter-2 inhibitors may decrease risk of in-stent thrombosis

Active surveillance strategies to improve rates of inferior vena cava filter retrieval

Nivolumab plus ipilimumab does not improve survival in post-nephrectomy patients with renal cell carcinoma

#VisualAbstract: Durvalumab, trametinib, and dabrafenib triplet therapy may provide robust immunogenicity in patients with BRAF-mutated advanced melanoma

Common hospital complications associated with COVID-19 identified in a retrospective cohort study

RelatedReports

Sodium-glucose co-transporter-2 inhibitors may decrease risk of in-stent thrombosis

Active surveillance strategies to improve rates of inferior vena cava filter retrieval

Nivolumab plus ipilimumab does not improve survival in post-nephrectomy patients with renal cell carcinoma

Adenoma detection rate is inversely associated with post-colonoscopy colorectal cancer risk

Common hospital complications associated with COVID-19 identified in a retrospective cohort study

O and Rh– blood groups may be associated with decreased risk for SARS-CoV-2 infection

#VisualAbstract AMLSG 09-09: Adding getuzumab ozogamicin (GO) to intensive therapy for Nucleophosmin1 mutated acute myeloid leukemia (NPM1mut AML) leads to better NPM1mut transcript clearance and a lower replase rate

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2MM+ Premium Access

Recent Reports

Want more physician-written
medical news?

#VisualAbstract SWOG-1211: Addition of elotuzumab to RVd induction and maintenance (lenalidomide, bortezomib, dexamethasone) did not improve patient outcomes in untreated, high-risk multiple myeloma

RELATED REPORTS

#VisualAbstract: Durvalumab, trametinib, and dabrafenib triplet therapy may provide robust immunogenicity in patients with BRAF-mutated advanced melanoma

Common hospital complications associated with COVID-19 identified in a retrospective cohort study

RelatedReports

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2MM+ Premium Access

Recent Reports

Want more physician-written medical news?

Want more physician-written
medical news?